Likewise, a prior treatment option for BLCA with high Siglec15 expression was to transform a non-inflamed TME into an inflamed TME and consequently trigger an anti-cancer immune response. This evidence concerns the gene SIGLEC15 and bladder transitional cell carcinoma.